

17TH IASLC WORLD CONFERENCE ON LUNG CANCER

NON-SMALL CELL LUNG CANCER: THE PROGRAMMED DEATH-LIGAND 1 (PD-L1) RECEPTOR AS A TARGET FOR MONOTHERAPY AND IN COMBINATION

Sunday, October 4, 2016
15.30–17.00

Hall C2
Messe Wien Exhibition & Congress Center
Vienna, Austria

Chaired by
Dr Sanjay Popat, National Heart and Lung Institute, London, UK

INVITATION

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.

This satellite symposium is sponsored by the Merck-Pfizer Alliance
Satellite Symposium held in conjunction with the 17th IASLC World
Conference on Lung Cancer

MERCK



AGENDA

TIME	SESSION	SPEAKER
15.30-15.45	Welcome and overview	Sanjay Popat (Chair) National Heart & Lung Institute, London, UK
15.45-16.00	Anti-PD-L1 monotherapy in non-small cell lung cancer (NSCLC): Overview of the trials examining anti-PD-L1 monotherapy in NSCLC	Rosalyn Juergens Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada
16.00-16.15	Anti-PD-L1 combined with other agents in NSCLC: Established and novel targeted agents	Jhanelle Gray H. Lee Moffitt Cancer Center & Research Institute, Florida, USA
16.15-16.30	Anti-PD-L1 combined with other agents in NSCLC: Immuno-oncology combinations	Sacha Rothschild Centre for Lung Tumours, University Hospital of Basel, Switzerland
16.30-16.45	Anti-PD-L1 agents: Opportunities for differentiation	Hossein Borghaei Fox Chase Cancer Center, Philadelphia, USA
16.45-17.00	Closing remarks and Q&A	Sanjay Popat (Chair) National Heart & Lung Institute, London, UK

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.

This satellite symposium is sponsored by the Merck-Pfizer Alliance Satellite Symposium held in conjunction with the 17th IASLC World Conference on Lung Cancer

MERCK

